Cue Biopharma, Inc. CUE
Nov 6, 2026, 1:18 PM EST
- YTD
- +99.78%
- 1 year
- -14.90%
- Market cap
- 131.92M
- Revenue (ttm)
- 8.29M
- EPS (ttm)
- -29.59
- Shares out
- 63.35M
- Forward P/E
- -1.79
- YTD return
- +99.78%
- 1-year return
- -14.90%
- Volume
- 142.22K
- Avg volume
- 260.99K
- Open
- 18.36
- Previous close
- 18.01
- Day's range
- 17.85 – 19.00
- 52-week range
- 4.98 – 45.50
- Beta
- 1.80
- Price target
- 3.60 (-80.3%)
- Earnings date
- Aug 14, 2024
5D -2.65 (-12.83%)
Key statistics
- Enterprise value
- 41.79M
- PEG ratio
- 0.00
- Price / sales
- 7.94
- Price / book
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 92.30%
- Free cash flow
- -20.00M
- Total cash
- 30.03M
- Total debt
- 11.26M
- Return on equity
- -138.87%
- Short % of float
- 2.98%
- 50-day average
- 1.31
- 200-day average
- 1.26
Analyst view
- Target (low)
- 2.00
- Target (mean)
- 3.60
- Target (high)
- 6.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.145.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.17 | +0.03 | +15.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | -0.20 | +0.09 | +31.03% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.30 | -0.25 | +0.05 | +16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Apr 8, 2024 | Dec 1, 2023 | 0.00 | -0.28 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2024 | Stifel | main | Buy | Buy |
| Jul 26, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jul 26, 2024 | Piper Sandler | main | Overweight | Overweight |
| Apr 9, 2024 | Stifel | main | Buy | Buy |
| Apr 9, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 3, 2024 | Piper Sandler | reit | Overweight | Overweight |
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cuebiopharma.com
News
12 Health Care Stocks Moving In Wednesday's After-Market Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
What's Going on With Cue Biopharma Stock on Monday? 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket 
Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis 
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83
Your note
Sign in to keep a note on CUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KIENER PETER A | Director | Sale | Mar 22, 2023 | 357 |
| PASSERI DANIEL R | Chief Executive Officer | Purchase | Dec 15, 2024 | 164,578 |
| SURI ANISH | President | Purchase | Aug 24, 2023 | 135,638 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bleichroeder LP | 7.89% | 4,997,240 | 5.20M | Sep 29, 2024 |
| Slate Path Capital, LP | 3.79% | 2,402,455 | 2.50M | Sep 29, 2024 |
| Vanguard Group Inc | 3.21% | 2,031,421 | 2.11M | Sep 29, 2024 |
| Blackrock Inc. | 0.90% | 570,975 | 593.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.80% | 508,827 | 529.18K | Sep 29, 2024 |
| Robertson Stephens Wealth Management, LLC | 0.76% | 478,500 | 497.64K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.13% | 1,347,078 | 1.40M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.94% | 597,569 | 621.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 276,050 | 287.09K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.17% | 110,814 | 115.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 88,916 | 92.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 66,386 | 69.04K | Oct 30, 2024 |